Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels
Beteiligte:
Wiegand, Johannes;
Wedemeyer, Heiner;
Finger, Andrea;
Heidrich, Benjamin;
Rosenau, Jens;
Michel, Gerd;
Bock, C Thomas;
Manns, Michael P;
Tillmann, Hans L
Erschienen:
SAGE Publications, 2008
Erschienen in:Antiviral Therapy
Sprache:
Englisch
DOI:
10.1177/135965350801300402
ISSN:
1359-6535;
2040-2058
Entstehung:
Anmerkungen:
Beschreibung:
<jats:sec><jats:title>Background</jats:title><jats:p>The elimination of hepatitis B virus surface antigen (HBsAg) is the final goal of hepatitis B treatment, but is rarely achieved. As quantitative assays for HBsAg recently became available, we have investigated whether quantitative HBsAg measurements can substitute for hepatitis B virus (HBV) DNA quantification in treatment monitoring.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Within this study, 23 liver transplant patients and 18 heart transplant recipients were retrospectively analysed. Patients had been treated with famciclovir and/or lamivudine, in addition some had also received adefovir in cases of lamivudine resistance. Quantitative HBsAg and hepatitis B virus e antigen (HBeAg) levels were determined with the Architect<jats:sup>TM</jats:sup>assay. HBV DNA levels were determined with different assays available at given time points.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>We did not find a significant correlation between either HBsAg or HBeAg and HBV DNA levels – both in treated and untreated patients. More importantly, there was no significant concordance between an increase or decrease of HBsAg or HBeAg with HBV DNA. However, the curve and decline of quantitative HBsAg enabled prediction of eventual viral clearance. Eight patients showed a 2 log<jats:sub>10</jats:sub>drop of HBsAg levels and eight patients demonstrated a reduction of HBsAg levels below 100 IU/ml; five patients fulfilled both criteria. Three of those five cleared HBsAg and became positive for antibodies against HBsAg.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Quantitative HBsAg and HBeAg cannot substitute for HBV DNA quantification during the assessment of antiviral therapy; however, the decline of HBsAg does predict eventual HBsAg clearance. A 2 log<jats:sub>10</jats:sub>drop to below 100 IU/ml is associated with a high likelihood of HBsAg clearance.</jats:p></jats:sec>